Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

XBIT - XBiotech Inc.

IEX Last Trade
7.585
0   0%

Share volume: 441,112
Last Updated: Mon 23 Dec 2024 04:41:06 PM CET
Research and Development in Biotechnology (except Nanobiotechnology): 0.45%

PREVIOUS CLOSE
CHG
CHG%
$7.58
-1.00
0.15%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
9%
Profitability 0%
Dept financing 1%
Liquidity 75%
Performance 3%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
4.76%
1 Month
-7.00%
3 Months
-6.04%
6 Months
40.53%
1 Year
62.76%
2 Year
107.14%
Key data
Stock price
$7.58
P/E Ratio 
-8.43
DAY RANGE
$6.59 - $7.58
EPS 
-$0.76
52 WEEK RANGE
$3.94 - $9.96
52 WEEK CHANGE
$62.76
MARKET CAP 
194.964 M
YIELD 
N/A
SHARES OUTSTANDING 
30.463 M
DIVIDEND
$2.0995
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$90,851
AVERAGE 30 VOLUME 
$73,902
Company detail
CEO: John Simard
Region: US
Website: xbiotech.com
Employees: 100
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

XBiotech Inc. discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis.

Recent news